Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations

Clinical Cancer Research

Volumn 20, Issue 2, 2014, Pages 404-412

  Lindholm, Evita M ^a   Krohn, Marit ^b   Iadevaia, Sergio ^e   Kristian, Alexandr ^a   Mills, Gordon B ^e   Mælandsmo, Gunhild M ^a,d   Engebraaten, Olav ^a,c  

^a Department of Tumor Biology ^*  (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DACTOLISIB; DOXORUBICIN; G 4408; GEFITINIB; GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN MICROARRAY; PROTEOMICS; REVERSE PHASE PROTEIN ARRAY; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MODEL; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MICE; NEOPLASMS, BASAL CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892735302     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1865     Document Type: Article

References (31)

1. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase 3 study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:3239-3247.
2. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2- negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-1260.
3. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combinationwith chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29:4286-4293.
4. Bergers G, Benjamin LE Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
5. Bergers G, HanahanDModes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
6. Casanovas O, Hicklin DJ, Bergers G, Hanahan D Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
7. Lindholm EM, Kristian A, Nalwoga H, Kruger K, Nygard S, Akslen LA, et al. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts. Mol Oncol 2012;6:418-427.
8. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5:2512-2521.
9. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001;20:1981-1989.
10. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in nonmicrodissected human breast cancers. Clin Proteomics 2010;6: 129-151.
11. Bergamaschi A, Hjortland GO, Triulzi T, Sorlie T, Johnsen H, Ree AH, et al. Molecular profiling and characterization of luminal-like and basallike in vivo breast cancer xenograft models. Mol Oncol 2009;3: 469-482.
12. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-1577.
13. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB Nonparametric quantification of protein lysate arrays. Bioinformatics 2007;23:1986-1994.
14. Iadevaia S, Lu YL, Morales FC, Mills GB, Ram PT Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 2010;70:6704-6714.
15. Dabbs DJ, Chivukula M, Carter G, Bhargava R Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 2006;19:1506-1511.
16. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271.
17. Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007;8:258.
18. Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010;116:1234-1242.
19. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010;70:1625-1634.
20. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and geneexpression subtypes of breast cancer. Genes Chromosomes Cancer 2006;45:1033-1040.
21. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-541.
22. Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, Kruger K, et al. In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts. J Magn Reson Imaging 2010;35:1098-1107.
23. Grinde MT, Moestue SA, Borgan E, Risa O, Engebraaten O, Gribbestad IS 13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns. NMR Biomed 2011;24:1243- 1252.
24. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, et al. Phosphorylation and activation of p70s6k by PDK1. Science 1998;279:707-710.
25. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 2008;105:17414- 17419.
26. Cavallaro U, Schaffhauser B, Christofori G Cadherins and the tumour progression: is it all in a switch? Cancer Lett 2002;176:123-128.
27. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clinical Cancer Res 2007; 13:7003-7011.
28. Boyer B, Valles AM, Edme N Induction and regulation of epithelialmesenchymal transitions. Biochem Pharmacol 2000;60:1091-1099.
29. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee- Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003;63: 2172-2178.
30. Moestue SA,DamCG, Gorad SS, Kristian A, Bofin A, MaelandsmoGM, et al. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Res 2013;15:R16.
31. Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2007;13:378-381.